MARKET

APTOF

APTOF

Aptose Bioscienc
OTCMQB
1.670
0.000
0.00%
Closed 12:37 02/13 EST
OPEN
1.690
PREV CLOSE
1.670
HIGH
1.690
LOW
1.670
VOLUME
310
TURNOVER
524
52 WEEK HIGH
7.76
52 WEEK LOW
0.700
MARKET CAP
4.26M
P/E (TTM)
-0.1917
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at APTOF last week (0202-0206)?
Weekly Report · 5d ago
Weekly Report: what happened at APTOF last week (0126-0130)?
Weekly Report · 02/02 09:27
Weekly Report: what happened at APTOF last week (0119-0123)?
Weekly Report · 01/26 09:26
Weekly Report: what happened at APTOF last week (0112-0116)?
Weekly Report · 01/19 09:29
Weekly Report: what happened at APTOF last week (0105-0109)?
Weekly Report · 01/12 09:28
Weekly Report: what happened at APTOF last week (1229-0102)?
Weekly Report · 01/05 09:27
Weekly Report: what happened at APTOF last week (1222-1226)?
Weekly Report · 12/29/2025 09:26
Weekly Report: what happened at APTOF last week (1215-1219)?
Weekly Report · 12/22/2025 09:26
More
About APTOF
Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

Webull offers Aptose Biosciences Inc stock information, including OTCMQB: APTOF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APTOF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APTOF stock methods without spending real money on the virtual paper trading platform.